RESULTS:
The basic data of the initial group, the additional patients, and the groups combined are as follows More than 1 course: 2 courses: 10 patients 3:1 4:1 6:1
CONCLUSIONS:
Additional experience continues to evidence to evidence the advantages of a very low dosing regimen of imiquimod 5% cream in the treatment of VAIN because of its simplicity of use, its high degree of effectiveness after a short treatment course, and the relative absence of associated adverse events.
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